Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Edwards Lifesciences Corporation and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$105.850.0%Nov 12 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Edwards Lifesciences sells catheter-delivered heart valves and repair devices, plus surgical replacement valves, to hospitals treating people with heart valve disease.
Company outlook: revenue of $1.7B to $1.8B for Fiscal Q4 2026 — up 8.9% on a year earlier